Aug. 8, 2025
| Today’s news and insights for biopharma leaders
The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an acquisition of its one-time COVID-19 vaccine competitor.
|
The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded to drugs like Keytruda.
|
The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many pharmaceutical companies have promised to build.
|
Despite several pullbacks in the field in the last decade, there are signs neurology is again a priority in some corners of the industry. Explore the latest developments and where the industry is headed in
|
Q&A
Decades-long research has yielded a strong and growing franchise built around drugs for a genetic form of lung cancer.
|
News roundup
Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.
|
UPDATED
In its latest earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly costs.
|
|
Real-world data (RWD) is crucial for healthcare decision-making. Learn best practices for maximizing regulatory, payer, HEOR and commercial impact through strategic data management in this playbook.
|
|
From Our Library
Trendline
Supported by Marken
|
Trendline
Supported by Bio-Rad
|
Trendline
Supported by Catalent
| | 
